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Abstract (<200 words) 
Purpose of review: Cerebral microbleeds (CMBs) are a radiological marker of cerebral small 
vessel disease corresponding to small haemosiderin foci identified by blood-sensitive MRI. 
CMBs are common in older community populations, and in individuals with ischaemic stroke 
(IS) or TIA, and intracerebral haemorrhage (ICH). We summarize how CMBs might 
contribute to assessing the future risk of IS and ICH to inform antithrombotic (antiplatelet or 
anticoagulant) decisions.  
Recent findings: CMBs are a risk factor for future IS and ICH in all community and hospital 
populations studied. Following IS/TIA treated with antithrombotics, increasing CMB burden 
increases the risk of ICH more steeply than that of IS. In ICH populations the risk of 
recurrent ICH increases with CMB burden, and is highest in those with strictly lobar CMBs 
or other haemorrhagic findings (e.g. cortical superficial siderosis) suggesting cerebral 
amyloid angiopathy (CAA).  
Summary: In IS or TIA patients <5 CMBs should not affect antithrombotic decisions, though 
with >5 CMBs the risks of future ICH and IS are finely balanced, and antithrombotics might 
cause net harm. In lobar ICH populations, a high burden of strictly lobar CMBs is associated 
with CAA and high ICH risk; antithrombotics should be avoided unless there is a compelling 
indication.  
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Introduction 
Although cerebral microbleeds (CMBs) have been extensively investigated since their first 
description in 1996 (1), important questions about underlying mechanisms and clinical 
relevance remain unanswered. CMBs are the radiological correlate of haemosiderin-laden 
macrophages resulting from small, usually chronic haemorrhages (2-4). Interest has focussed 
on CMBs as a potential marker of a “bleeding prone” small vessel arteriopathies, with 
potential to predict symptomatic intracerebral haemorrhage (ICH) risk (5, 6). However, 
CMBs are also a risk factor for ischaemic stroke (7, 8), possibly explained by alternative 
“ischaemic” pathophysiological mechanisms(9-11). Antithrombotic (antiplatelet and 
anticoagulant) use in patients with CMBs is a highly topical clinical dilemma (12), which will 
become increasingly common with an aging population often investigated with MRI and 
exposed to antithrombotic drugs for stroke and cardiovascular prevention. This review 
provides up-to-date information on the clinical relevance of CMBs for antithrombotic use.    
 
Definition, mechanisms and potential relevance of CMBs for antithrombotic decisions 
CMBs are defined radiologically as small (generally <10 mm) ovoid or rounded black signal 
voids on paramagnetic-sensitive MRI sequences, including T2* gradient-recalled echo 
weighted and susceptibility-weighted imaging(13).  CMBs must be differentiated from 
“mimics” (13), and account taken of technical imaging aspects affecting detection (14-16). 
Standardised rating scales or automated techniques can improve reliability of CMB rating 
(17-19). Studies of the pathological correlates of CMBs include only 23 patients (4, 20) 
mainly with ICH or dementia. Nevertheless, most observations suggest that CMBs are self-
limiting regions of red cell extravasation from damaged small blood vessels. CMB location 
predicts the type of underlying small vessel disease: an arteriopathy associated with systemic 
arterial hypertension and pathological changes in small perforating arteries of the deep grey 
and white matter (often termed “hypertensive arteriopathy’) causes CMBs in deep (basal 
ganglia) as well as lobar regions. In Western (Caucasian) people with ICH, CMBs in a 
strictly lobar distribution are highly specific for cerebral amyloid angiopathy (CAA), which 
causes progressive deposition of amyloid-β in small cortical and leptomeningeal arterial 
walls(3), though this pattern might not be so specific in Eastern (Asian) people and in those 
without ICH(21, 22). Figure 1 shows the different radiological distributions of CMBs.  
 
More recently, ischaemic mechanisms for CMBs have been identified: ischaemia-mediated 
iron store released by oligodendrocytes; (9) phagocytosis of red cell microemboli into the 
perivascular space (termed angiophagy); (10) and haemorrhagic transformation of 
microinfarcts (11), which might contribute to the clinical associations between CMBs and 
future IS risk.  
 
CMBs might be relevant for ICH risk with antithrombotic exposure: first, CMBs are common 
in populations likely to be exposed to antithrombotic drugs, including older community-
dwelling individuals and those with IS, TIA or ICH (23); and second, longitudinal studies 
confirm that CMBs are a dynamically develop over time after IS, TIA or ICH (24, 25) (while 
regression of CMBs can occur, it seems to be rare). Since antithrombotics impair haemostasis 
by inhibiting platelet aggregation (antiplatelets) or disrupting the coagulation pathway 
(anticoagulants), in the presence of a CMB-related arteriopathy, normally self-limiting red 
blood cell extravasation (causing a CMB) could become a symptomatic ICH (Figure 2). 
 
 
Current evidence on clinical outcomes following antithrombotic use in different 
populations evaluated for CMBs 
When CMBs are detected in a patient with a risk of future ischaemic vaso-occlusive disease, 
should antithrombotic drugs be recommended? Without randomised trial data, the best 
evidence is from prospective observational cohorts and pooled meta-analyses. We suggest 
considering: the population (non-stroke, IS/TIA, or ICH); the type of antithrombotic 
(antiplatelet or anticoagulant); the overall risk of IS and ICH; CMB presence, burden and 
distribution; the balance of future IS and ICH; and judgement of the likely net benefit and 
harm of antithrombotic treatment (Table 1). 
  
Table 1. Summary of evidence on IS and ICH risk by CMB presence, burden and distribution 
 
 Non-stroke (older 
community) 
 
Ischaemic stroke and 
TIA 
Intracerebral 
haemorrhage 
Effect of CMB 
presence  
 
(compared to no 
CMBs) 
IS risk 
  
Absolute event rate 
2.6% over a mean 
follow up of 4.9 
years 
HR 1.52; 95% CI 
0.91 to 2.53 (23) 
HR 4.48; 95% CI 
2.20 to 12.2 (26) 
 
ICH risk 
  
Absolute event rate 
0.7%  over a mean 
follow up of 4.9 
years 
HR 5.64; 95% CI 
1.66 to 19.53 (23) 
HR 50.2; 95% CI 
16.7 to 150.9 (26) 
IS risk  
  
Absolute event rate 
9% over a median 
follow up of 18 
months  
Absolute risk increase 
3.4%. 
Pooled risk ratio 1.8  
(27) 
 
ICH risk  
 
Absolute event rate 
over a median follow 
up of 18 months 4.3% 
Absolute risk increase 
3.8%. 
Pooled risk ratio 6.3 
(27) 
 
ICH risk 
 
Baseline CMBs 
associated with 
recurrent ICH in lobar 
but not deep ICH (28)  
Effect of CMB 
burden  
 
(all data compared 
to those without 
CMBs) 
All stroke risk 
 
 
Increased risk of ‘all 
stroke’ with 2-4 
CMBs and >5 CMBs 
(23) 
IS risk  
>5CMBs 
 
Absolute event rate 
10.5% over a median 
follow up of 18 
months 
Absolute risk increase 
5.1% 
Pooled risk ratio 2.7 
(27) 
 
ICH risk  
>5CMBs 
 
Absolute event rate 
over a median follow 
up of 18 months 8.8%  
Absolute risk increase 
8.2% 
Pooled risk ratio 14.1 
(27) 
 
Increasing CMB 
burden (29) 
All cause mortality 
ICH risk  
 
 
Baseline number of 
CMBs associated with 
recurrent ICH in lobar 
but not deep ICH (28) 
 
>5 CMBs 
HR 4.12 95% CI 1.6 
to 9.3  in patients with 
CAA-related ICH (30) 
 
3 year cumulative risk 
51% in those with 
lobar ICH (5) 
HR 1.99; 95% CI 1.03 
to 3.85  
IS mortality 
HR 3.39; 95% CI 1.39 
to 8.28. 
Effect of CMB 
distribution  
 
(compared to no 
CMBs) 
Strictly lobar 
(probable CAA)  
 
IS risk 
Absolute event rate 
1.4% over a mean 
follow up of 4.9 
years 
HR 0.84; 95% CI 
0.41 to 1.74 (23) 
 
 
ICH risk  
Absolute event rate 
0.6% over a mean 
follow up of 4.9 
years 
HR 5.27; 95% CI 
1.38 to 20.23 (23) 
 
5 cases/100 patient 
years (31) (median 
10 CMBs in these 
patients) 
 
 
Not strictly lobar 
(i.e. not probable 
CAA) (23) 
 
IS risk  
Absolute events rate 
1.4% over a mean 
follow up of 4.9 
years 
HR 3.05; 95% CI 
1.65 to 5.63 
 
 
 
 
ICH risk  
Absolute event rate 
0.6% over a mean 
follow up of 4.9 
Strictly lobar 
(probable CAA) 
 
IS risk  
Absolute event rate 
over a median follow 
up of 18 months 9.3% 
Absolute risk increase 
3.9%. 
Pooled risk ratio 2.0 
(27) 
 
ICH risk  
Absolute event rate 
over a median follow 
up of 18 months 3.6% 
Absolute risk increase 
3.2 % 
Pooled risk ratio 10.5 
(27) 
 
 
ICH mortality 
HR 5.91; 95% CI 1.58 
to 22.11(29) 
 
Mixed CMBs 
 
 
 
IS risk  
Absolute event rate 
over a median follow 
up of 18 months 
10.7% 
Absolute risk increase 
5.3% 
Pooled risk ratio 2.6 
(27) 
 
 
ICH risk  
Absolute event rate 
over a median follow 
up of 18 months 6.1% 
Probable CAA 
patients 
 
ICH risk  
 
3 year cumulative ICH 
rates (5) 17% 2  
strictly lobar CMBs,  
37% 3-5 strictly lobar 
CMBs, 
51% strictly lobar 
CMBs 
 
8.9 events/ 100 patient 
years (31) 
 
2-4 CMBs (30) 
HR 2.9; 95% CI 1.3 to 
4.0;  
 
>5 CMBs (30) 
HR 4.12; 95% CI 1.6-
9.3 
 Non-stroke (older community) populations 
The diagnostic accuracy of a strictly lobar CMB pattern for CAA seems limited in non-ICH 
(community) cohorts: in a recent study strictly lobar CMBs had a positive predictive value for 
pathology-proven CAA of only 25% (32), though participants had very few CMBs (33). 
years 
HR 5.27; 95% CI 
1.07 to 32.86 
 
Absolute risk increase 
5.7% 
Pooled risk ratio 11.1 
(27) 
 
Antithrombotic-
CMB interactions 
Antiplatelets did not 
significantly change 
IS or ICH risk 
according to CMB 
presence, burden or 
distribution(23) 
Risks outlined above 
(excluding ICH 
mortality) are for 
patients largely on 
antiplatelets. No data 
on interaction 
available.  
 
ICH mortality was 
from patients on 
anticoagulants.  
ICH risk in CAA 
 
Aspirin 
HR 3.95; 95% CI 1.6 
to 8.3(30) 
Conclusions and 
recommendations 
CMBs increase the 
risk of both ICH and 
IS. Those in a strictly 
lobar distribution 
have a higher risk of 
ICH.  
However, currently 
neither presence, 
burden or 
distribution should 
routinely affect 
antithrombotic 
decisions 
CMBs increase the 
risk of both IS and 
ICH. An increasing 
burden increased the 
risk of ICH more 
dramatically than the 
risk of IS, but 
absolute rates of IS 
remain higher at all 
CMB counts.  
Although CMBs 
should generally not 
affect antithrombotic 
decisions, in IS or 
TIA patients with a 
large number of 
CMBs (e.g.>5) the 
risks of future ICH 
and IS are finely 
balanced, and 
antithrombotics 
might cause net 
harm. Further studies 
are needed in patients 
on anticoagulants. 
CMBs presence and 
increasing burden 
increase the risk of 
ICH.  
Patients with lobar 
ICH with a high 
burden of strictly 
lobar CMBs or other 
haemorrhagic 
markers (e.g. cortical 
superficial siderosis), 
should if possible 
avoid 
antithrombotics. 
NOACs are preferable 
to VKA. LAAO is an 
option in ICH patients 
with AF.  
Longitudinal studies of outcome related to CMBs in community cohorts are shown in Table 
1. In the Rotterdam study (23) of 4759 participants aged ≥45 years with mean follow-up of 
4.9 years, CMBs were associated with an increased risk of all stroke (HR 1.93; 95% CI 1.25 
to 2.99); this was lower (and not statistically significant) for IS (HR 1.52; 95%CI 0.91 to 
2.53) than for ICH (HR 5.64; 95% CI 1.66 to 19.53). Non-strictly lobar CMBs (i.e. non-CAA 
pattern), were associated with an increased the risk of both IS and ICH while strictly lobar 
CMBs (indicating probable CAA) were associated only with ICH risk. Six participants with 
multiple CMBs developed a first-ever ICH during follow-up; 3 had used antithrombotic 
agents (either platelet inhibitors or oral anticoagulants). However, the overall stroke risk 
associated with CMBs was not affected by the use of antithrombotics. Pre-existing CMBs 
were associated with lacunar infarction whilst incident lobar CMBs are associated with 
progression of white matter lesions, suggesting shared ischaemic mechanisms.  
A large Japanese population-based study showed that CMB presence was associated with 
both IS (hazard ratio 4.48; 95 % CI 2.20 to 12.2) and ICH (hazard ratio 50.2; 95 % CI 16.7 to 
150.9)(26), but did not explore CMB burden, topography, or associations with 
antithrombotics. A hospital-based study in patients with incidental lobar CMBs without 
stroke reported ICH rates comparable to CAA-associated ICH (31) and that warfarin was an 
independent risk factor for ICH (p=0.02). However, this population had a median of 10 lobar 
CMBs, suggesting severe CAA, so these findings cannot be generalised to other stroke-free 
populations with incidentally found CMBs. 
 
In summary, in community-dwelling populations, there is no clear evidence that the benefits 
of IS prevention by the use of antithrombotic drugs outweigh the risk of ICH in people with 
CMBs. Further interventional controlled clinical trials, including stratification according to 
CMB presence, burden and distribution, will be needed to definitively answer this question.  
  
Ischaemic stroke and TIA populations 
The clinical relevance of CMBs is perhaps most uncertain in the IS and TIA population, 
because standard care includes antithrombotics for stroke secondary prevention. Does any 
increased risk of ICH in patients with CMBs outweigh the benefit in reducted future IS risk 
associated with antithrombotic therapy? Although risk instruments can be used to assess 
overall future IS risk in AF (e.g. CHA2DS2VASC) or after TIA (ABCD2), as well as overall 
bleeding risk in AF (e.g. HAS-BLED), there are currently very limited data on how CMBs 
and other brain imaging findings might help personalise antithrombotic therapy to maximise 
benefit and minimise risk.  
In recent studies, antiplatelets (34-36) and anticoagulants (36, 37) are associated with the 
presence of CMBs and the development of new CMBs over time. However, establishing the 
clinical relevance of CMBs requires key clinical outcomes, including recurrent stroke. A 
recent aggregate data meta-analysis from 15 studies of patients with IS or TIA including 5068 
patients over a median of 18 months follow-up showed that baseline CMBs are associated 
with an increased risk of both IS (pooled RR 1.8; 95% CI 1.4 to 2.5) and ICH (pooled RR 
6.3; 95% CI 3.5 to 11.4) (27) . The risk ratio for both IS and ICH increased with CMB 
burden, but more steeply for ICH than IS: in individuals with >5 CMBs the RR of IS was 2.7, 
while that of ICH was 14.1 (Figure 3). At all CMB counts, the absolute risk of IS exceeded 
that of ICH, though in those with >5 CMBs, the absolute risk of ICH (8.8%) approached that 
of IS (10.5%). In randomised trials, antiplatelet agents only modestly reduce the absolute risk 
of ischemic stroke (0.5 to 2.5%) (38), while the recent meta-analysis showed that ≥5 CMB 
are associated with an absolute risk increase of 8.2% for ICH and 5.1% for IS. Since ICH is 
generally more severe than IS, it is possible that in individuals with >5 CMBs, antithrombotic 
treatment may be associated with net harm. The prevalence of patients with ≥5 CMBs ranged 
from 12 to 51%, suggesting this dilemma will be encountered often in clinical practice. 
However, since most individuals in this meta-analysis were treated with antithrombotic drugs 
(79% with antiplatelets, 15% with anticoagulants), it cannot be concluded that CMBs should 
be avoided in patients with >5 CMBs. The benefit of antithrombotics in IS/TIA patients with 
many (e.g. >5) CMBs will only be determined by randomised controlled trials. Nevertheless, 
these data do provide reassurance that in individuals with IS or TIA and <5 CMBs, there is 
no suggestion that antithrombotics are hazardous, so should be used according to current care 
guidelines. 
 
Data on the association between CMBs and stroke risk on patients with IS or TIA treated 
with anticoagulants are extremely limited. A small study in 134 patients with TIA or IS 
associated with AF (65% treated with anticoagulants) over a median follow-up of 2.4 years 
(39), found that CMBs were associated with an increased unadjusted risk of all stroke (21% 
vs 9%, p = 0.06) but there was only 1 ICH. A study from Korea in 504 patients with IS or 
TIA (97% discharged on anticoagulation) (29) found that strictly lobar CMBs were 
associated with ICH mortality (HR 5.91; 95% CI 1.58 to 22.11) whilst increasing CMB 
burden was associated with all cause (HR 1.99; 95% CI 1.03 to 3.85) and IS mortality (HR 
3.39; 95% CI 1.39 to 8.28) but did not report on non-fatal IS or ICH. A retrospective study 
from the same Korean group including 550 ischaemic stroke patients with AF (83% 
discharged on anticoagulation) found that higher CHADS2 and CHA(2)DS(2)VASC scores 
were associated with the presence and number of CMBs. Recurrent ICH was associated with 
CMB presence (HR 3.79; 95 % CI 1.09 to 13.15) but not CHADS2 or CHA(2)DS(2)VASC 
scores; recurrent IS risk was not reported (40). A small prospective single centre study from 
Japan followed 119 patients with AF (86% anticoagulated) for a median of 17 months (41); 
CMBs were not associated with recurrent stroke (both ICH and IS), but due to the small 
number of events IS and ICH risk could not be  examined separately. 
 
There is thus an urgent need for more large-scale data on how CMBs might affect the balance 
of IS and ICH in IS/TIA patients treated with oral anticoagulants. Two large large multicentre 
inception cohort studies will help to address this gap:  Clinical Relevance of Microbleeds in 
Stroke (CROMIS 2; see https://www.ucl.ac.uk/cromis-2, 
https://clinicaltrials.gov/ct2/show/NCT02513316)(42) and Intracerebral Hemorrhage Due to 
Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance (HERO; see 
http://heropub.pic.es, https://clinicaltrials.gov/ct2/show/NCT02238470). 
ICH populations 
The most feared, often lethal, complication of antithrombotic therapy is ICH. Recurrent ICH 
risk varies according to the location of the initial ICH: the annual ICH recurrence risk after 
deep (non-lobar, in the basal ganglia or brainstem) ICH is between 1.3 to 10.6% compared 
with 2.5 to 28.2% after lobar ICH. (43) While deep ICH is attributed to hypertensive 
arteriopathy, lobar ICH may be due to either hypertensive arteriopathy or CAA. Cohort 
studies in CAA-related ICH or CMBs, diagnosed according to the Boston criteria indicate a 
high recurrence rate of ~10% per year (31).  The presence, burden and distribution of CMBs 
might increase the risk of recurrent ICH, and help to judge difficult antithrombotic decisions 
(Table 1). In a study of 207 survivors of ICH followed for a median of 20 months there were 
39 recurrences of ICH(28). CMB number was associated with recurrent ICH in patients with 
lobar but not deep ICH, while antiplatelet use did not affect the risk of recurrent ICH in either 
lobar (HR 0.8; 95% CI 0.3 to 2.3, p = 0.73) or deep location (HR 1.2; 95% CI 0.1 to 14.3, p = 
0.88). By contrast, a small single centre study in CAA-related ICH reported that aspirin was 
an independent risk factor for recurrent ICH (HR 3.95; 95% CI 1.6 to 8.3, p = 0.021) (30). 
 Three other studies found that increasing CMB burden is associated with increasing ICH risk 
(5, 6, 30), but none reported on IS risk. Two of these studies included only patients with lobar 
ICH, whilst the third included both deep and lobar ICH. The risk of ICH was particularly 
high with >5CMBs (HR 4.12 95% CI 1.6 to 9.3 vs. no CMBs p = 0.001 (30) with a 51% 3 
year cumulative risk for >5 CMBs vs. 14% 3 year cumulative risk for 1 CMB p = 0.003(5).  
 
The use of anticoagulants following ICH thus presents a major clinical dilemma. The risk of 
ischaemic stroke without antithrombotic treatment must be weighed carefully against the 
possible increase in ICH risk associated with antithrombotic therapy. A decision analysis 
which modelled warfarin for AF in an ICH survivor suggested that in lobar ICH avoiding 
warfarin increased quality-adjusted life (QOL) years by 1.9, compared with 0.3 for deep ICH; 
the authors concluded that anticoagulation for AF should not be offered to patients with lobar 
ICH and only to survivors of deep ICH if the risk of ischaemic events was high (>7% per 
year)(44). However, CMBs were not considered in this analysis. By contrast, recent real-
world studies in large datasets from ICH survivors with AF suggest that anticoagulation 
reduces mortality and ischaemic complications, without an increase in ICH (45, 46), and also 
reduced hospitalization costs (47). However, none of the real world studies stratified ICH by 
location, nor by CMB burden or distribution. Further studies in ICH cohorts phenotyped 
according to CAA diagnostic criteria, with assessment of interactions of CMB pattern and 
burden with antithrombotic use may help clarify this enduring clinical dilemma. Two 
ongoing randomised trials of antithrombotic use after ICH will also help guide clinicians in 
these decisions in future: APACHE-af (http://apache-af.nl –aspirin vs. apixaban vs. 
noantithrombotics for the treatment of AF in patients after ICH) and RESTART 
(www.restarttrial.org –antiplatlets vs, no antiplatelets in patients with ICH with an indication 
for antiplatelets). 
 
Other imaging markers 
Other imaging markers of small vessel disease include cortical superficial siderosis (cSS), 
leukoaraiosis and enlarged perivascular spaces. cSS seems to be strongly associated with 
probable CAA(48, 49) and with increased recurrent ICH risk(49-51), especially if  
disseminated (49).  
 
 
 
Conclusion 
Cerebral microbleeds are a risk factor for both future IS and ICH in all populations studied, 
including healthy older people people, and those with IS, TIA or ICH. Following IS or TIA 
treated with antithrombotics, increasing CMB burden increases the risk of ICH more steeply 
than that of IS; in patients with a large number of CMBs (e.g.>5) the risks of future ICH and 
IS are finely balanced, and antithrombotics might cause net harm. However, most of the 
evidence in IS and TIA cohorts is from patients treated with antiplatelet agents rather than 
anticoagulants. Large global collaborative networks will be needed to obtain the necessary 
data to assess any potential hazard of CMBs, especially associated with the use of in 
anticoagulants; the Microbleeds International Collaborative Network(52) will undertake a 
systematic review and individual patient data meta-analysis of the clinical relevance of CMBs 
in patients with TIA and ischaemic stroke treated with antithrombotics (the prospectively 
registered protocol is published at: 
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016036602).  
ICH patients with probable CAA (i.e. those with lobar ICH and either strictly lobar CMBs or 
disseminated cortical superficial siderosis) have a high baseline annual risk of ICH (>5% per 
year), which is likely to be increased substantially with the use of anticoagulants. We suggest 
that these patients should usually avoid anticoagulation; if essential to prevent further 
ischaemic events (e.g. in the presence of high risk atrial fibrillation), non-vitamin K 
antagonists are preferable because of a lower risk of ICH(53). Alternatives to anticoagulation 
for patients with AF include left atrial appendage occlusion (54), which is as effective as oral 
anticoagulants but likely to have lower future ICH risk than long-term oral anticoagulation in 
ICH survivors. Figure 4 is a treatment algorithm suggested by the authors based on current 
evidence. 
 
 
Key points 
 CMBs can be due to both haemorrhagic and ischaemic mechanisms, and are 
associated with an increased risk of both IS and ICH in all populations studied, 
including community-dwelling older adults, IS or TIA, and ICH   
 CMBs should not currently influence antithrombotic decisions in non-stroke 
(community-dwelling) populations 
 In IS or TIA populations, a small number of CMBs (<5) is associated with a higher 
risk of recurrent IS than ICH, so should not routinely influence antithrombotic 
decisions 
  In patients with IS or TIA treated with antithrombotics, an increasing burden 
(number) of CMBs is associated with a steep increase in ICH risk: individuals with a 
high CMB burden (>5) have similar absolute risks of ICH and recurrent IS, so that 
antithrombotic use might cause net harm  
 CMBs and other haemorrhagic imaging markers (e.g. cortical superficial siderosis) 
are associated with a substantial risk of recurrent CAA-related ICH, and current 
limited evidence suggests that avoiding antithrombotics is probably appropriate in 
individuals with this high risk profile    
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**van Veluw SJ, Biessels GJ, Klijn CJ, Rozemuller AJ. Heterogeneous histopathology 
of cortical microbleeds in cerebral amyloid angiopathy. Neurology. 2016;86(9):867-71 
Recent histopathological correlation study which reveals CMBs have a heterogeneous 
histopathological substrate suggesting multiple different mechanisms 
 
*Janaway BM, Simpson JE, Hoggard N, Highley JR, Forster G, Drew D, et al. Brain 
haemosiderin in older people: pathological evidence for an ischaemic origin of MRI 
microbleeds. Neuropathology and applied neurobiology. 2013. 
 
*Grutzendler J, Murikinati S, Hiner B, Ji L, Lam CK, Yoo T, et al. Angiophagy 
prevents early embolus washout but recanalizes microvessels through embolus 
extravasation. Science translational medicine. 2014;6(226):226ra31. 
Both of the above papers give mechanistic insights into the possible ischaemic mechanisms 
which may lead the formation fo CMBs. 
 
*Microbleeds International Collaborative Network. Worldwide collaboration in the 
Microbleeds International Collaborative Network. Lancet neurology. 2016 Volume 15, 
Issue 11, October 2016, Pages 1113–1114 
A global collaborative effort which will help answer key questions about CMBs and stroke 
risk. Only large international efforts will have statistical power to address prediction of rare 
outcomes, including antithrombotic-related ICH.  
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Figure titles 
 
Figure 1: Distribution of microbleeds. 
A. Mixed distribution of microbleeds in both deep (thalamic and basal ganglia) and lobar 
regions; this pattern is hypothesised to be due to either severe hypertensive arteriopathy, or 
mixed hypertensive arteriopathy and cerebral amyloid angiopathy  
B. Strictly lobar distribution of microbleeds, suggesting a diagnosis of probable cerebral amyloid 
angiopathy (CAA) 
 
Figure 2: Hypothetical possible mechanisms of CMBs and intracerebral haemorrhage.  
 
Figure 3: Risk ratio of both ischaemic stroke and intracerebral haemorrhage depending on 
CMB burden in patients with ischaemic stroke or TIA 
Legend: CMB –cerebral microbleeds; TIA-transient ischaemic attack; IS –ischaemic stroke; ICH – 
intracerebral haemorrhage 
 
Figure 4: Suggested decision making algorithm for antithrombotic use in patients with CMBs 
based upon the authors recommendations 
Legend: TIA –transient ischaemic attack; ICH –intracerebral haemorrhage; CMB –cerebral 
microbleed; AF –atrial fibrillation; LAA –left atrial appendage; CAA –cerebral amyloid angiopathy;  
RESTART - REstart or STop Antithrombotics Randomised Trial; APACHE-AF - Apixaban versus 
Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral 
HaEmorrhage in patients with Atrial Fibrillation.  
